BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

  • Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients. • Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum. • Full enrollment expected in Q2 2026.

  January 13, 2026

   · 

  7 min read
• Press Releases

  Esomeprazole Market to Reach USD 3.17 Billion by 2032 Driven by GERD Prevalence

  January 13, 2026

   · 

  1 min read
• Press Releases

  Myocardial Ischemia Market to Reach US$ 7.98 Billion by 2032, Driven by Rising Cardiovascular Disease Burden

  January 13, 2026

   · 

  1 min read
• Press Releases

  Meloxicam Market Surpassed USD 12.34 Billion in 2032 Amid Rising Arthritis and Chronic Pain Cases

  January 13, 2026

   · 

  1 min read
• Press Releases

  Botox Market Size to worth US$ 12.57 Billion by 2032, Coherent Market Insights

  January 13, 2026

   · 

  1 min read
• 

  Manufacturing

  J&J To Add 500 Jobs at New Plant, Doubling Down on North Carolina

  Johnson & Johnson’s second facility in Wilson, North Carolina, is part of a $55 billion push to make all advanced medicines used in the U.S. domestically.

  January 13, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor
• 

  Policy

  Acadia CEO Bands With Peers To Lobby Against MFN Drug Pricing for Small Biotech

  Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.

  January 13, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Events

  JPM26: Confident Merck Sees Growth Through Keytruda Loss of Exclusivity

  Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the company is open to deals in the range of “multi tens of billions of dollars.”

  January 13, 2026

   · 

  1 min read

   · 

  Heather McKenzie
• 

  Deals

  JPM26: Attendees Wonder, Where’s Our Big M&A Deal?

  There hasn’t been a headline-stealing deal at J.P. Morgan yet. Nevertheless, the mood is positive amid green shoots and a flurry of dealmaking to end 2025.

  January 13, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  obesity

  JPM26: Novartis Doesn’t Have a GLP-1. They Don’t Miss It In a World Of Me-Toos

  Speaking to BioSpace at the J.P. Morgan Healthcare Conference, Novartis’ chief dealmaker Ronny Gal explains why the Swiss pharma hasn’t acquired a GLP-1, and why it probably won’t.

  January 13, 2026

   · 

  3 min read

   · 

  Annalee Armstrong